Table 2.
Univariate Probability of Outcome
| Allogeneic (N = 232) | Autologous (N = 62) | ||||
|---|---|---|---|---|---|
| Outcomes | N Eval | Prob (95% CI) | N Eval | Prob (95% CI) | P-value |
| Relapse | 230 | 61 | |||
| 1 -year | 10 (6-14)% | 21 (11-32)% | 0.14 | ||
| 3-year | 16 (12-22)% | 28 (17-40)% | 0.34 | ||
| 5-year | 18 (14-24)% | 30 (19-42)% | 0.40 | ||
| Treatment related mortality | 230 | 61 | |||
| 1 -year | 28 (22-34)% | 2 (0-8)% | <0.001 | ||
| 3-year | 30 (24-36)% | 5 (1-14)% | <0.001 | ||
| 5-year | 31 (25-37)% | 7 (2-17)% | <0.001 | ||
| Disease free survival | 230 | 61 | |||
| 1 -year | 62 (56-68)% | 78 (66-87)% | 0.02 | ||
| 3-year | 54 (47-60)% | 67 (54-78)% | 0.07 | ||
| 5-year | 50 (44-57)% | 63 (49-75)% | 0.10 | ||
| Overall survival | 232 | 62 | |||
| 1 -year | 66 (60-72)% | 93 (85-98)% | <0.001 | ||
| 3-year | 58 (52-65)% | 79 (67-88)% | 0.002 | ||
| 5-year | 54 (48-61)% | 75 (63-85)% | 0.002 | ||